XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Jun. 30, 2024
Dec. 31, 2023
Current Assets    
Cash and cash equivalents $ 11,304 $ 6,841
Short-term investments 50 252
Accounts receivable (net of allowance for doubtful accounts of $82 in 2024 and $88 in 2023) 11,642 10,349
Inventories (excludes inventories of $3,456 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6) 6,469 6,358
Other current assets 8,740 8,368
Total current assets 38,205 32,168
Investments 357 252
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,960 in 2024 and $18,266 in 2023 23,221 23,051
Goodwill 21,161 21,197
Other Intangibles, Net 16,984 18,011
Other Assets 12,702 11,996
Total Assets 112,630 106,675
Current Liabilities    
Loans payable and current portion of long-term debt 3,071 1,372
Trade accounts payable 3,519 3,922
Accrued and other current liabilities 14,712 15,766
Income taxes payable 2,777 2,649
Dividends payable 1,981 1,985
Total current liabilities 26,060 25,694
Long-Term Debt 34,717 33,683
Deferred Income Taxes 876 871
Other Noncurrent Liabilities 7,329 8,792
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023 1,788 1,788
Other paid-in capital 44,362 44,509
Retained earnings 60,187 53,895
Accumulated other comprehensive loss (5,361) (5,161)
Stockholders' equity before deduction for treasury stock 100,976 95,031
Less treasury stock, at cost: 1,041,454,052 shares in 2024 and 1,045,470,249 shares in 2023 57,394 57,450
Total Merck & Co., Inc. stockholders’ equity 43,582 37,581
Noncontrolling Interests 66 54
Total equity 43,648 37,635
Liabilities and Equity $ 112,630 $ 106,675